MEBENDAZOLE GENERIC PRODUCTS MUST UNDERGO CLINICAL OUTCOMES STUDIES
Executive Summary
MEBENDAZOLE GENERIC PRODUCTS MUST UNDERGO CLINICAL OUTCOMES STUDIES as a requirement for ANDA approval, FDA said in a July 1 letter to Janssen Pharmaceutica. "Because of mebendazole's poor bioavailability and nonsystemic action, FDA will require generic applicants to perform in vivo studies and in vitro dissolution testing using the test or reference product from the same batch" of the oral anthelminthic, the agency said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: